Combined GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy for Adults with Type 2 Diabetes and Chronic Obstructive Pulmonary Disease: A Large-Scale Target Trial Emulation
- Design
- Retrospective cohort · 17467 participants · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Different population[Auto] Participants had type 2 diabetes (age/BMI not reported in abstract).
- Could weight loss explain it?
- Possibly[Auto] Participants had obesity and/or type 2 diabetes and the abstract does not separate direct drug effects from weight loss or glycaemic improvement.
- Study tier
- Preliminary[Auto] Not peer reviewed (preprint, abstract or registration). Early-warning only.
- Assessment
- Version 1 · automatic, not yet reviewed by a person · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75. This item has not been peer reviewed.
[Auto, unreviewed; last sentences of abstract] Conclusions Among adults with T2DM and COPD who reached the 90-day landmark, initiation of GLP-1RA plus SGLT2i therapy was associated with modest but statistically significant reductions in all-cause mortality, COPD exacerbation, and pneumonia compared with SGLT2i initiation alone. These complementary relative and absolute associations support further evaluation of combination therapy as a potentially beneficial option for selected high-risk patients.</p>
01Findings
What the study reported
- Drugs
- Class unspecified
- Comparator
- the SGLT2i-only strategy
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- 4 years
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Diabetes status
- type 2 diabetes present (all or most)
- Sample size
- 17467
Study quality details
- Study design
- Retrospective cohort
- Sample size
- 17467
- Randomization
- no
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- 4 years
- Outcome type
- hard
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- CI reported: 95% confidence interval [CI] 0
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- no
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- not available in metadata
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
<title>Abstract</title> <p>Background Adults with type 2 diabetes mellitus (T2DM) and chronic obstructive pulmonary disease (COPD) experience substantial cardiometabolic and respiratory risk. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) provide established metabolic, cardiovascular, and renal benefits, clinical outcomes associated with their combined use in this comorbid population remain uncertain. Methods We conducted a target trial emulation using the TriNetX US Collaborative Network (2018–2023). Adults with T2DM and COPD who initiated a GLP-1RA plus SGLT2i strategy were compared with those who initiated an SGLT2i-only strategy. Propensity score matching (1:1) balanced demographics, socioeconomic and lifestyle factors, comorbidities, medications, laboratory parameters, and available healthcare-utilization proxies. Follow-up began at a 90-day landmark and continued for up to 4 years. All-cause mortality was the primary outcome; COPD exacerbation and pneumonia were key secondary outcomes. Results After matching, 17,467 patients were included in each group. Compared with the SGLT2i-only strategy, the combination strategy was associated with lower risks of all-cause mortality (hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.81–0.93), COPD exacerbation (HR 0.93; 95% CI 0.89–0.97), and pneumonia (HR 0.93; 95% CI 0.89–0.98). At 4 years, the corresponding absolute risk reductions were 2.27%, 2.07%, and 1.59%. No significant between-group differences were observed for dialysis initiation, major adverse cardiovascular events, emergency department visits, or hospitalization. Conclusions Among adults with T2DM and COPD who reached the 90-day landmark, initiation of GLP-1RA plus SGLT2i therapy was associated with modest but statistically significant reductions in all-cause mortality, COPD exacerbation, and pneumonia compared with SGLT2i initiation alone. These complementary relative and absolute associations support further evaluation of combination therapy as a potentially beneficial option for selected high-risk patients.</p>
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| europepmc | Sep 13, 2026 | PPR:PPR1308671 first ingestion |